Hims & Hers stands firm in face of PhRMA slur

7 February 2025

Trade group the Pharmaceutical Research and Manufacturers of America (PhRMA) has accused one of the country’s largest compounders, Hims & Hers, of running a misleading multi-million dollar Super Bowl advert, saying that it ‘misrepresents its unapproved GLP-1 medicines’.

Hims & Hers has defended itself in the face of the accusations, saying that it is simply seeking to offer Americans that are served by a broken health system, with affordable and available options.

But PhRMA argues that the advert runs afoul of the Federal Food, Drug, and Cosmetic Act (FDCA), which requires that advertising for prescription drugs - including compounded drugs - not be false or misleading.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK